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Abstract: The association between rheumatoid arthritis (RA) and periodontal disease (PD) has
been the focus of numerous investigations driven by their common pathological features. RA is
an autoimmune disease characterized by chronic inflammation, the production of anti-citrullinated
proteins antibodies (ACPA) leading to synovial joint inflammation and destruction. PD is a chronic
inflammatory condition associated with a dysbiotic microbial biofilm affecting the supporting tissues
around the teeth leading to the destruction of mineralized and non-mineralized connective tissues.
Chronic inflammation associated with both RA and PD is similar in the predominant adaptive
immune phenotype, in the imbalance between pro- and anti-inflammatory cytokines and in the role
of smoking and genetic background as risk factors. Structural damage that occurs in consequence
of chronic inflammation is the ultimate cause of loss of function and disability observed with the
progression of RA and PD. Interestingly, the periodontal pathogen Porphyromonas gingivalis has been
implicated in the generation of ACPA in RA patients, suggesting a direct biological intersection
between PD and RA. However, more studies are warranted to confirm this link, elucidate potential
mechanisms involved, and ascertain temporal associations between RA and PD. This review is mainly
focused on recent clinical and translational research intends to discuss and provide an overview of
the relationship between RA and PD, exploring the similarities in the immune-pathological aspects
and the possible mechanisms linking the development and progression of both diseases. In addition,
the current available treatments targeting both RA and PD were revised.
Keywords: periodontal disease; rheumatoid arthritis; alveolar bone loss; bone; periodontitis;
bone resorption
1. Introduction
The possible association between rheumatoid arthritis (RA) and periodontal disease (PD) has been
investigated because of the numerous similarities in pathological and immunological characteristics,
including: (1) Increased infiltration of inflammatory and immune cells including neutrophils,
monocytes, and T and B lymphocytes; (2) increased release of pro-inflammatory mediators such as the
tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), and matrix-degrading
enzymes (MMPs, Cathepsin); (3) increased activation of the receptor activator of the factor nuclear
kappa B (NF-κB) ligand (RANK-L) pathway induced by soluble mediators released by immune
cells [1], with subsequent osteoclast differentiation and maturation. In addition, decreased levels of
anti-inflammatory mediators, such as the IL-10 and transforming growth factor-β (TGF-β) are also
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reported in both RA and PD [2–5]. PD and RA also lead to systemic inflammation, indicated by
increased levels of the C-reactive protein (CRP) in the plasma [6]. Environmental factors (smoking)
and genetic background (gene polymorphisms) are also considered risk factors for both conditions.
A summary of the overlapping features of RA and PD is presented in Figure 1.
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Figure 1. Possible biological intersecti atoid arthritis (RA) and periodontal disease
(PD): Com on risk/predisposing factors and r i l i l ical influences. Th exposure to certain
environmental factors, e.g., smoking, ge etic ac r ( LA-DRB1-SE), gut microbiome, infection
with P. gingivalis and ore recently with A. actinomycete comitans (microbial dysbiosis) leads to
local protein alteration by citrullination. In combination with an infla matory process stimulated by
macrophages, dendritic cells, and T cells, a host response to citrullinated proteins in predisposed patients
will occur. Immune cells will produce proinflammatory mediators (Interleukins (ILs), Prostaglandins
(PGs), Tumor Necrosis Factor (TNF), and metalloproteinases (MMPs), which also contribute to the
aggravation of the immune response. IL-17, an important cytokine of the Th17 induces the production
of CXC chemokines, MMPs, and reactive oxygen species (ROS), as well as the osteoblast expression of
the receptor activator of the factor nuclear kappa B ligand (RANK-L) that stimulate osteoclast activation.
Stimulated lymphocytes (B and T cells, specifically Th1 and Th17) play an important function during
bone resorption by means of the RANKL-dependent mechanism in both conditions. P. gingivalis infection
lead to the activation of proteases and peptidylarginine deiminase (PPADs) that generates citrullinated
proteins and triggers the synthesis of anti-citrullinated proteins antibodies (ACPAs). A resultant
signal against citrullinated epitopes in the joints resulting in enhanced expression of the rheumatoid
factor (RF) and ACPAs, assisting in the formation of immune complexes. A. actinomycetemcomitans
lead to the hypercitrullination of neutrophils and result in the activation of citrulline enzymes, which
are also involved in the breakdown of the immune tolerance to the host molecules. These immune
complexes enhance the host inflammatory development, which may aggravate RA. In addition, the
autoantibodies produced during this process might contribute to the inflammatory process by directly
activating osteoclast and resulting in the bone and cartilage damage. Thus, citrullination may represent
a biological mechanism bridging reciprocal influences between RA and PD.
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In spite of differences in the etiologies of RA (autoimmune) and PD (dysbiotic microbial biofilm),
there are similar biological processes involved, such as citrullination and autoantibody response [7,8]
and the pivotal role of bacterial dysbiosis, which may represent direct links between these two
conditions [1,9–11]. Citrullination of peptides is mediated by peptidylarginine deiminase (PAD) and
is considered a key event in RA [12,13]. Recently, it was reported that the periodontal pathogen
P. gingivalis express PAD, may represent a direct biological intersection between PD and RA [13–17].
Accordingly, recent studies have strengthened the hypothesis that PD is a risk factor for the RA
development [18,19]. The authors showed that individuals at high risk to develop RA were presented
with an increased prevalence of PD and periodontopathogenic bacteria (P. gingivalis) suggesting that
PD is associated with disease initiation and could be targets for preventive interventions in RA.
In support to a biological link between PD and RA, there is a much higher prevalence of RA in PD
patients (3.95%, compared to 1% in the general population) [20]. Interestingly, in the greater severity of
RA (swollen joints), an increased erythrocyte sedimentation rate (ESR), and increased CRP are correlated
with more severe periodontal bone resorption [21]. Previous case-control studies [22–25] showed
that long-term smoking increases the risk for RA development. Furthermore, the epidemiological
association between smoking and RA became the center of innumerous researches when smoking was
recognized as a trigger to the citrullination of peptides via stimulation of the PAD enzyme [26]. In line
of this, cigarette smoking has been associated with an increased risk of seropositive disease (ACPA
and RF) [27]. Accordingly, a more aggressive form of PD, characterized by an increased periodontal
attachment apparatus loss and bone resorption, is seen in smokers compared to non-smokers control
patients [28–31]. However, it is important to bear in mind that several studies in the literature mention
statistical or selection adjustment/control for smoking, and most of them (if not all) consider smoking
as a categorical variable (current, former or never-smoker) and do not account for the frequency, type
or duration of smoking. This is also true for the socioeconomic status of patients suffering from PD
and/or RA. In this context, further randomized clinical trials are warranted to investigate the possible
influence of cigarette consumption based on the frequency, type and duration of smoking in patients
striking from both conditions.
This review discusses the information on mechanisms underlying the possible reciprocal influences
between RA and PD, particularly those related to the similarities in the immune-pathological aspects,
and also the current available therapeutic strategies targeting RA and PD.
2. Periodontal Disease
Periodontitis, the most common cause of tooth loss in humans [32], is one of the world’s most
prevalent chronic inflammatory disease, affecting 46% of the United States population, according to the
National Health and Nutrition Examination Survey (NHANES) [33], with 10–15% of the PD patients
having a more aggressive form of the disease [34]. The ultimate outcome of PD is the loss/extraction of
teeth that are no longer capable of supporting the functional demands, causing a significant impact on
the oral health-related quality of life [35–37]. The economic burden of dental diseases is exceptionally
elevated, with treatment expenses anticipated at 416 billion US dollars per year worldwide [38]. More
than 70% of this spending goes toward the treatment of PD. In the United Kingdom, 3 to 4 million
individuals (approximately 5% of the UK population) currently suffer from severe PD at a cost of
2 billion pounds/year to the National Health Service (NHS) [39]. In the past three decades, a number of
studies has reported associations between periodontitis and various systemic inflammatory conditions,
including arthritis, type 2 diabetes mellitus, and atherosclerosis [40–42].
PD is a chronic inflammatory condition of the supporting tissues (gingiva, periodontal ligament and
alveolar bone) around the teeth, caused by a dysbiotic microbial biofilm on the tooth surfaces [34,43,44].
Most of the tissue destruction results from the host immune triggered and sustained by the dysbiotic
process [34]. The dysbiosis causing the shift from the periodontal health to PD is analogous to that in
the intestinal mucosal surfaces, as a stable microbial community comprised mostly by Gram-positive
aerobes is changed to a pathogenic bacterial community characterized microaerophilic and anaerobic
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Gram-negative microorganisms. Three bacterial species are strongly correlated with PD: P. gingivalis,
Treponema denticola and Tannerella forsythia, referred to as the “red complex” [45–47].
The molecular events that occur during PD pathogenesis are briefly described in Figure 2.
Importantly, as a chronic inflammatory condition, both microbial- and host-derived molecular patterns
(PAMPs and DAMPs) accumulate in the microenvironment alongside with the innate and adaptive
immune cells [48–50] producing numerous inflammatory mediators, such as TNF-α, IL-1β, IL-6, IL-17,
prostaglandin E2 (PGE2), growth factors, and degrading enzymes (collagenase, elastase, gelatinase),
which are the main culprits of the destruction of the tooth-supporting structures [51–53], in a process
somewhat analog to autoimmune conditions [54–56].
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Figure 2. The pathogenesis of the periodontal disease. A dysbiotic microbiome localized in the enamel
surface of the tooth, below the gingival margin, initiate the innate immunity by stimulating resident cells
(epithelial cells, periodontal ligament fibroblast, and gingival fibroblast and dendritic cells) to produce
mediators of inflammation in response to bacter al lipopolysacch ide (LPS) (via the toll-like receptor).
Resident cells located in the connective tissue and alveolar bone produce proinflammatory cytokines
and chemokines, including (Tumor Necrosis Factor- α (TNF-α), Interleukin-1 β (IL-1β), IL-6, IL-8,
IL-12, IL-17 and the receptor activator of the factor nuclear kappa B ligand (RANK-L). Microorganisms
located in the biofilm can reach the connective tissue and goes toward the alveolar bone, leading to the
expression of RANK-L by osteoblasts, which can be accounted for the bone resorption seen during the
disease process. If the infection fails to resolve, the release of pro-inflammatory mediators will continue
and the activation of the B and T cells initiates the adaptive immunity. In this stage, the connective
tissue become infiltrated by lymphocytes with predominantly more B cells (RANK-L) than T cells.
The T cells will produce TNF-α, RANK-L and IL-17 which lead to increased osteoclastogenesis and
bone resorption. This will result in the clinical signs of the disease characterized by increased clinical
attachment loss (CAL.).
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Variations in the host response to the microbial antigens derived from genetic influences and from
acquired risk factors (e.g., systemic conditions affecting the immune response, medications, tobacco
use) account for the significant variation in the susceptibility and severity of PD [2,57,58]. Like RA, PD
is considered to be of a multifactorial condition, and systemic inflammatory disorders (such as RA)
can lead to disturbing the equilibrium between the host and oral microbiota, assisting the onset of PD
and/or enhancing the destruction of periodontal tissues.
Clinical characteristics of PD include friable gums, spontaneous bleeding, gingival recession,
deepening pockets surrounding the tooth (indicating alveolar bone resorption), and eventual tooth
loosening [59]. The diagnosis of PD is mainly based on clinical and intra-oral radiographic examination,
involving bleeding on probing (BOP), probing pocket depth (PPD), clinical attachment level (CAL)
and alveolar bone level [60]. The main therapy for the periodontitis treatment is based on the control
of the oral biofilm by improving oral hygiene and removing plaque and dental biofilm through scaling
and root planning. Of importance, there are variations in the periodontitis case definition and in the
criteria for the severity of involvement that might compromise comparisons of the results reported by
different studies. Moreover, few studies have reported the inflammatory status (bleeding on probing)
as a criterium for the evaluation of the periodontal disease status.
3. Rheumatoid Arthritis
Rheumatoid arthritis (RA), a chronic autoimmune disease, is depicted by synovial inflammation
and hyperplasia leading to irreversible damage of the cartilage and bone in the joints, loss of function,
chronic pain and progressive disability (stiffness, swelling and deformation of the joints) [61–63]. RA
affects up to 1% of the population worldwide, is three times more prevalent in women, and is associated
with significant co-morbidities (cardiovascular illness, skeletal disorders such as: Periarticular bone
loss, juxta-articular bone erosion, joint ankyloses and fractures) [5], socioeconomic burden, and
mortality [4]. The exact etiology of RA is still poorly understood although it is hypothesized that the
development of RA is dependent on the complex associations between environmental factors (e.g.,
long-term smoking), genetic background, hormonal, and infectious risk factors [64–66] resulting in the
formation of autoantibodies and the onset of RA.
The diagnosis of RA is based on physical examination (according to the European League
Against Rheumatism—EULAR criteria) [67], clinical history, and laboratory tests (presence of ACPAs
and/or RF antibodies, abnormal acute phase reactants such as CRP and ESR), and also by imaging
methods, such as magnetic resonance imaging (MRI) and ultrasonography methods [68]. The Disease
Activity Score including the 28-joint count (DAS28) is also used in the clinical assessment of the
disease activity calculated with a formula based on the number of swollen and tender joints, the
patient’s global assessment based on a visual analog scale (VAS, 0–100) and measurements of CRP and
ESR [69]. The management of RA is primarily based on medications, such as: Analgesics, non-steroidal
anti-inflammatory drugs (NSAIDs), and biologic and non-biologic disease-modifying antirheumatic
drugs (DMARDs), physical therapy, and surgery aiming at reducing symptoms, slowing joint damage
progression and achieving remission [70,71].
The pathological aspects of RA include hyperplasia of the synovial membrane lining due to
an influx of inflammatory cells (T and B lymphocytes, macrophages, neutrophils, and dendritic
cells) into the synovium and joint cavity, resulting in the exacerbated production of cytokines and
proteases. The overproduction of pro-inflammatory cytokines, such as TNF-α, IL-1β, IL-6, IL-17,
the granulocyte macrophage colony-stimulating factor (GM-CSF), and RANKL is central to the
pathogenesis of RA. These cytokines drive joint destruction by stimulating synovial fibroblasts and
chondrocytes to secrete collagen-degrading enzymes (matrix metalloproteinases, MMPs) and by
activating osteoclast differentiation leading to the cartilage and bone destruction [61,72–75]. The major
cellular and molecular events in the pathogenesis of RA are represented in Figure 3.
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responses that ultimately result in the cartilage and bone destruction. Macrophages, synovi l fibroblast,
and dendritic cells pro uce several pro-inflammatory mediat rs such as Interleukins (IL-1, IL-2,
L-6, IL-10, IL-13, IL-15, 17, IL-18, Tumor Necrosis Factor- α (TNF-α), Granulocyte macrophage
colo y-stimulating factor (GM-CSF), and metallopr teinases (MMPs). In addition, the T cells activatio
lea s to overproduction of inflammatory cytokines, including TNF- , IL-1b, and IL-6 by macrophages.
The overexpression of infl mmatory cytokin enhances the capacit to i duce the production of
RANKL, which is the main regulator of osteoclastoge esis. These cells of the innat mmun system
hold extensive proinflam at ry, destructive, a d remodeling capacities, and substantially ontribute
to inflamma on and joint destruction in RA.
In the last few years, there has been an increased focus on the role of citrullination and production
of autoantibodies in the pathogenesis of RA. The level of anti-citrullinated protein antibodies (ACPA)
is a highly specific marker of the disease (95–98% specificity) [59] and has been shown to be present in
the serum of 70% of RA patients up to a decade rior to the initial effective diagnosis [2,76]. ACPA
can be detected by a diagnostic test based on the reactivity against the synthetic cyclic citrullinated
peptide (anti-CCP) [26,77]. The ACPA-positive RA is associated with a more severe disease compared
to the ACPA-negative disease patients [78]. The presence of the rheumatoid factor (RF), a polyclonal
antibody that reacts to the Fc portion of immunoglobulin G (IgG), is another diagnostic criterion for
RA. In contrast to the ACPA, RF has only limited specificity for early detection of the disease and can
be detected in several other diseases [79,80]. It has been shown that RF by itself does not contribute to
the RA disease progression [81].
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More recently, a role for the microbiome in the pathogenesis of inflammatory arthritis has been
suggested as a possible modifier agent (environmental factor) in the disease development [82–86]. The
connection of the gut microbiome in the arthritis pathogenesis was supported by the observation that
experimental arthritis in both the IL-1 knockout and K/BxN animal models of RA was strongly attenuated
under germ-free conditions [87,88]. Mucosal surfaces such as the lung, intestine and periodontal
tissues are sites of the immune surveillance and a breach of the immune tolerance may contribute to
development of arthritis [84,89]. This is sustained by the statement that autoantibodies (anti-PAD4,
RF, antibodies against carbamylated proteins (anti-CarP), and ACPA,) might be distinguished years
before individuals have joint symptoms [76,90]. Hypothetically, autoimmune responses initiated in
microbially-colonized mucosal surfaces can transition to extramucosal sites like the synovial joints
contributing to the signs and symptoms characteristic of RA [83,91–93]. Lately, it has been demonstrated
that RA patients had a higher bacterial load, increased abundance of pathogenic species, and a more
diverse oral microbiota associated with PD compared to the healthy controls (with RA and without PD),
which resulted in worse periodontal condition (clinical attachment loss) in those patients. Moreover,
changes in the oral microbiome (increased pathogenic species such as Prevotella, Aggregatibacter
actinomycetemcomitans and Parvimonas micra) were associated with poor RA conditions (number of
tender and swollen joints) in patients with RA-PD [43].
In the context of the microbiome in the pathogenesis of rheumatic disease, microorganisms
located in the gut and in the periodontal tissues (extra-articular) play an important role as potential
initiators of immune-mediated inflammatory conditions at distant sites [94] (Figure 4). The oral
environment possesses its own particular microbiota with more than 700 different species [95], which
is located below the gingival margin (connective tissue) with a permeable epithelium. There are
some hypotheses in which the microbiota may be involved in the progression of the disease, such
as: Epithelial and mucosal permeability, loss of immune tolerance to components of the microbiota,
and trafficking of immune cells to the joints [94]. In this context, periodontal pathogens can reach
the blood circulation as a consequence of frequent and low intensity bacteremia induced by chewing
or tooth brushing [96]. Once microorganisms gain access to the peripheral blood, they can colonize
distant sites in the body and eventually initiate the pathological processes. Of importance, the DNA
of P. gingivalis, Treponema denticola, Prevotella intermedia, Prevotella nigrescens, Tannerella forsythia and
Fusobacterium nucleatum have been detected in the synovial fluid of patients with RA. Moreover,
elevated titers of antibodies against T. forsythia, P. intermedia and P. gingivalis have been detected in the
serum and synovial fluid of RA patients [97–100]. It has been suggested that an increased amount
of Gram-negative microorganisms in the intestines increased toxic metabolites that reached blood
circulation and may eventually enhance joint inflammation [101].
With significance to the pathogenesis of RA, there is a growing understanding of mucosal
environmental exposures and dysbiosis as possible causal events during the onset of RA. One of the
hypothesis raised is associated with the immunoglobulin A (IgA)-related autoimmunity (ACPA) as a
potential causative link in the RA development, which is centered on the autoantibody isotype and
plasmablast studies [102,103]. In this regard, Barra et al. [102] determined the prevalence of various
ACPAs in first-degree relatives and found that the rate of the ACPA positivity in unaffected RA patients
were very high. Moreover, in the first-degree relatives, ACPAs were not significantly associated with
the SE, smoking, symptoms of RA, or PD. The ACPA profile of those patients consisted predominately
of the IgA isotype and this outcome might be suggested as possible indicative of the IgA isotype in the
pathogenesis of RA. Holers et al. elegantly confirmed that the lung also plays an important role in the
pathogenesis of RA. They have demonstrated in subjects at high risk to RA development that the most
citrulline-specific antibody response in the sputum were those to fibrinogen, vimentin, apolipoprotein
E and fibronectin. Moreover, mucosal ACPA production in the lung, and possible in other tissues, is
associated with the presence of local inflammation and increased levels of neutrophil extracellular
traps (NET) formation. These findings supported the pivotal function of the lung in early RA related
autoimmunity [104–106]. They also suggested that the most important initial event in the preclinical
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development of RA is the loss of the mucosal barrier function and systemic spread of an IgG ACPA
response instead of the loss of tolerance to self-antigens [107]. However, studies evaluating mucosal
origins hypothesis are limited because not all of them enable the relationship of the precise mucosal
events present in the early time point or points during which such exposures would have influenced
the concurrent autoimmune phenotypes as well as subsequent RA development. In this context, more
studies are warranted to clarify those aspects.Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 8 of 34 
 
 
Figure 4. Potential initiators of immune-mediated inflammatory conditions at distant sites. A briefly 
description of the extra-articular potential initiators that might account for the pathogenesis of 
rheumatic diseases. Patients at high risk to develop autoimmune arthritis are more prone to infections 
due to endogenous (dysfunctional immune system) and external factors, i.e., periodontal disease and 
the presence of P. gingivalis and A. actinomycetemcomitans that trigger citrullinated peptides; exposure 
to risk factors such as smoke and pollutants might lead to the production of neutrophils extracellular 
traps (NEToses) and anti-citrullinated proteins antibodies (ACPA) in the lung; and the gut dysbiosis 
that also lead to the ACPA production. For patients at high risk to develop rheumatoid arthritis (RA), 
meticulous examining for infectious foci, particularly in the intestine and mouth, should be advocated 
in order to allow their early recognition and eradication. 
With significance to the pathogenesis of RA, there is a growing understanding of mucosal 
environmental exposures and dysbiosis as possible causal events during the onset of RA. One of the 
hypothesis raised is associated with the immunoglobulin A (IgA)-related autoimmunity (ACPA) as 
a potential causative link in the RA development, which is centered on the autoantibody isotype and 
plasmablast studies [102,103]. In this regard, Barra et al. [102] determined the prevalence of various 
ACPAs in first-degree relatives and found that the rate of the ACPA positivity in unaffected RA 
patients were very high. Moreover, in the first-degree relatives, ACPAs were not significantly 
associated with the SE, smoking, symptoms of RA, or PD. The ACPA profile of those patients 
consisted predominately of the IgA isotype and this outcome might be suggested as possible 
indicative of the IgA isotype in the pathogenesis of RA. Holers et al. elegantly confirmed that the lung 
also plays an important role in the pathogenesis of RA. They have demonstrated in subjects at high 
risk to RA development that the most citrulline-specific antibody response in the sputum were those 
to fibrinogen, vimentin, apolipoprotein E and fibronectin. Moreover, mucosal ACPA production in 
the lung, and possible in other tissues, is associated with the presence of local inflammation and 
increased levels of neutrophil extracellular traps (NET) formation. These findings supported the 
pivotal function of the lung in early RA related autoimmunity [104–106]. They also suggested that 
the most important initial event in the preclinical development of RA is the loss of the mucosal barrier 
function and systemic spread of an IgG ACPA response instead of the loss of tolerance to self-antigens 
[107]. However, studies evaluating mucosal origins hypothesis are limited because not all of them 
enable the relationship of the precise mucosal events present in the early time point or points during 
Figure 4. Potential initiators of i une- ediated infla atory conditions at distant sites. briefly
description of the extra-articular potential initiators that might account for the pathogenesis of rheumatic
diseases. Patients at high risk to develop autoimmune arthritis are more prone to infections due to
endogenous (dysfunctional immune system) and external factors, i.e., periodontal disease and the
presence of P. gingivalis and A. actinomycetemcomitans that trigger citrullinated peptides; exposure to
risk factors such as smoke and pollutants might lead to the production of neutrophils extracellular
traps (NEToses) and anti-citrullinated proteins antibodies (ACPA) in the lung; and the gut dysbiosis
that also lead to the ACPA production. For patients at high risk to develop rheumatoid arthritis (RA),
meticulous examining for infectious foci, particularly in the intestine and mouth, should be advocated
in order to allow their early recognition and eradication.
For a comprehensive review on the role of mucosa-environment interactions in the pathogenesis
of RA, the article made by Lucchino et al. [108] and a review paper made by the Holers group [107]
are recommended.
4. Mechanistic Studies Linking RA and PD
Studies on the possible mechanisms by which both diseases may be interconnected explore the
major molecular pathways associated with the pathogenesis of RA and PD.
4.1. Two-Hit Model Associating RA and PD
A possible association link between RA and PD is based on the theor of the “two-hit” model,
first described by Golub et al. [109]. In this theory, the first “hit” involves the increased presence of
anaerobic microorganisms and their antigens in the periodontal microenvironment. This initial hit
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triggers destructive events of periodontitis, such as increased production of bone-resorptive cytokines
(IL-6, IL-1, TNF-α) and tissue-destructive proteinases (MMPs). The second “hit” involves a systemic
disease, such as RA, that causes an increase of serological biomarkers of systemic inflammation (e.g.,
CRP, IL-6, IL-1β, PGE2, MMPs, and TNF-α). The increased serum levels of inflammatory mediators
may further stimulate immune cells in the periodontium and enhance the production of MMPs
and RANKL, aggravating destruction of non-mineralized and mineralized connective tissues in the
periodontium [109,110], in a process that closely resembles cytokine-driven osteoclast activation and
bone destruction during the pathogenesis of RA [26].
Similarly, Wegner et al. [111] suggested a “two-hit” model for PD influence on RA: The first
hit is initiated by increased prevalence of PAD-producing P. gingivalis in the periodontal disease
microenvironment, leading to increased local citrullination of peptidesband generation of APCAs.
The second hit is represented by cross-reactivity of periodontal-generated APCAs to antigens present
in the joint microenvironment, further aggravating the inflammation associated with RA. This
amplification of the autoimmune reaction would end into the chronic and damaging inflammation
that characterizes arthritis.
4.2. Genetic Susceptibility
Genetic variations are associated with both RA and PD. It is possible that some common genetic
traits are associated with increased susceptibility to these conditions. One potential genetic influence
connecting RA and PD is the shared epitope (SE)-coding HLA-DRB1 allele [112]. According to van
der Woude et al. [113] 50% of the risk to develop RA is attributed to genetic factors, and the most
relevant genetic association in RA is with the SE-coding HLA-DRB1 gene that confers more than 80%
of susceptibility for joint destruction [64,114]. The HLA-DRB1 alleles encoding the beta chain of class
II MHC can bind citrullinated peptides [115], possibly increasing the immunogenicity of the arthritis
auto-antigenic citrullinated peptides [115,116]. It has been demonstrated that interaction between
the elevated anti-RgpB IgG levels and the HLA–DRB1 SE was only detected in ACPA-positive RA
patients [117], supporting a role for this genetic variation in the response to citrullinated antigens.
The SE-coding DRB1 alleles have been associated with bone erosions in RA as well as alveolar
bone destruction during PD progression [118–120]. Recent data [112] shows that the transgenic mice
carrying a human SE-coding HLA-DRB1 allele present spontaneous alveolar bone resorption and
osteopenic skeletal changes, characterized by slenderer tibiae and decreased total bone area in the
marrow and cortical tibial bones. Furthermore, overexpression of pro-inflammatory cytokines IL-17
and TNF-α were also found in SE-positive mice. SE acts as a signal transduction ligand that facilitates
Th17 and osteoclast differentiation, increasing the RA severity [121–123]. These studies provided new
insights in the association of SE with bone erosions in the inflammatory diseases supporting a genetic
intersection between RA and PD.
The HLA-DRB1 SE has also been implicated as a risk factor for the periodontal disease [40,119,120].
Sandal et al. [124] demonstrated a potential role of HLA-DRB1 in the generation of ACPA in response
to P. gingivalis oral infection model in mice. The generation of ACPAs in transgenic mouse (I-A◦/I-E◦
on the C57BL/6 background that expresses susceptibility allele HLA-DRB1) required the expression of
the PAD enzyme for the citrullination of host-derived proteins, representing a possible causative link
between PD and RA [116]. This information supports the hypothesis of P. gingivalis as a possible source
of the PAD enzyme inducing citrullination of host-derived peptides and the subsequent production of
ACPAs that may cross-react with host-derived antigens in the joints and contribute/aggravate RA.
4.3. Bacterial Link Between PD and RA
Based on the microbial dysbiosis etiology of PD, increased interest has emerged in clarifying the
potential role of specific bacterial species in the link with RA [125].
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4.3.1. The Citrullination Process
The indirect involvement of P. gingivalis in the pathogenesis of RA through the expression of PAD
and the process of citrullination was first described in 2004 [45,111,126]. Citrullination is the process of
post-translational modification of the amino acid arginine into citrulline, which is mediated by PAD, an
enzyme of immune cells such as T and B lymphocytes, neutrophils, monocytes and macrophages [127],
leading to the production of anti-CCP antibodies [15]. The isoform PADI4 is the most important for
autoimmunity and is not active during homeostasis. When citrullinated proteins are formed in excess
they can act as autoantigens, leading to the production of auto-antibodies favoring the pathogenesis of
rheumatic diseases [128].
To date, P. gingivalis (the most common oral microorganism implicated in PD) is the only known
microorganism with the ability to express the PPAD enzyme (known as PPAD to distinguish this bacterial
enzyme from the human counterpart PAD). The PAD enzyme is directly associated with the formation
of ACPA and plays an important role in the pathogenesis of RA [14,126]. The post-translational
modification of arginine into citrulline through the PAD enzyme leads to the modification of the
protein structure, and in genetically susceptible (e.g., in shared epitope-positive) individuals this
might result in the generation of an immune response to citrullinated self-antigens. Citrullination
associated with the host-derived PAD may be augmented by bacterial-derived PADs and enhance the
production of ACPAs, which can precede the development of RA, and thus have an etiological role in
its pathogenesis [129].
In translational studies, a comparison of wild-type (WT) P. gingivalis with PAD-deficient
P. gingivalis or P. intermedia (without PAD) supports a role for PPAD as a mechanistic link between
P. gingivalis-induced periodontal infection and RA [130]. WT P. gingivalis drastically augmented levels
of autoantibodies to type II collagen and citrullinated epitopes whereas the PPAD-null mutant did
not. Interestingly, administration of the protein arginine deiminase inhibitor (Pan-PAD inhibitor,
Cl-amidine) diminishes the severity of the collagen-induced arthritis (CIA) in mice, indicating a
causative connection between PPAD and RA [131].
In addition to its ability to express PPAD, P. gingivalis induces the production of pro-inflammatory
cytokines (such as IL-6 and IL-1β) by the immune cells [132]. In this context, oral infection with
P. gingivalis previous to the RA induction enhances the immune system stimulating a Th17 cell response
that may accelerate arthritis development [133,134]. P. gingivalis has also the capacity to invade primary
human chondrocytes when cultured in vitro, affecting cellular responses, which can contribute to the
tissue damage during the RA pathogenesis [135,136]. All those characteristics of P. gingivalis suggest
that PD, associated with increased prevalence of this microorganism, can influence the development of
RA development through the citrullination process, the activation of Th17-related pathways. Taken
together, this information supports a pivotal role for P. gingivalis in the causal link between PD and
RA [137,138].
A clinical study investigated whether P. gingivalis influence the titer of ACPA in patients. They
have concluded that in patients with PD, oral infection might be accountable for inducing autoimmune
responses that characterizes RA [139]. It was suggested that RA-susceptible patients presenting PD
may be exposed to citrullinated antigens produced by PPAD, which might lead to intra-articular
inflammation [126]. PAD citrullinated peptides result in the expression of RF-containing immune
complexes, leading to a local inflammatory reaction, both in the periodontal tissues and synovium,
through Fc and C5a receptors [126]. This suggests a reciprocal influence of PD and RA, mediated by
ACPAs and RF.
The prevalence of P. gingivalis in the oral microbiota of RA patients is strongly correlated with
the presence of ACPA and it has been hypothesized that increased accumulation of citrullinated
proteins and the reduced immunotolerance of RA subjects to citrullinated proteins lead to an increased
formation of autoantibodies [140]. The increased formation of citrullinated proteins is associated with
a more aggressive form of the disease and with earlier development of bone erosions [138]. A previous
well-designed study has shown that ACPA concentrations were elevated among RA patients with PD
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and were associated with the presence of antibodies against P. gingivalis. The authors also showed that
increased alveolar bone resorption was correlated with higher ACPA concentrations [137].
Although P. gingivalis is the PD-related microorganism most well-studied in the pathogenesis of
RA, a recent study identified another periodontal pathogenic microorganism, A. actinomycetemcomitans,
a Gram-negative coccobacillus, as a potential trigger for the pathogenesis of RA, providing a
novel connection with PD [16]. This study established that A. actinomycetemcomitans induced
hypercitrullination in host neutrophils by dysregulated activation of citrullinating enzymes through
the pore-forming toxin leukotoxin A (LtxA—a major virulence factor of A. actinomycetemcomitans),
resulting in a citrullinome that parallels as observed locally in RA-affected joints [16]. The same
study also demonstrated that LtxA induced changes in the neutrophil morphology with the release of
citrullinated proteins. Furthermore, exposure to leukotoxic A. actinomycetemcomitans was confirmed in
RA patients with PD and was positively associated with ACPA levels. Emphasizing this relationship
between the A. actinomycetemcomitans and RA development, the same group showed recently that the
clinical symptoms of arthritis (morning stiffness, tenosynovitis, polyarthritis) and anti-CCP antibodies
were successfully diminished when the antibiotic treatment against A. actinomycetemcomitans was
prescribed for the patient, which was presented with A. actinomycetemcomitans endocarditis [141].
Furthermore, a potential role of the periodontopathogenic bacteria P. intermedia in the pathogenesis
of RA was further elucidated in a study made by Schwenzer et al. [142]. This study was performed
to clarify the mechanism by which PD could induce ACPAs, by examining the antibody response
to a novel citrullinated peptide of cytokeratin 13 (CK-13) identified in the GCF of RA patients. The
outcomes of this study have identified ACPA fine specificities associated with P. intermedia. Antibodies
to cCK13-1 correlated strongly with anti-cTNC5, both of which were linked to a serologic response to
P. intermedia infection pointing to the role of this bacteria in the pathogenesis of RA. However, previous
pre-clinical studies [143,144] did not demonstrate the role of P. intermedia in the pathogenesis of RA, as
described further below.
4.3.2. Modulation of Immune Response by PD-Associated Bacteria
Oral inoculations with live P. gingivalis appeared to sensitize mice and rats to early RA development
and increased the severity of joint destruction. An interesting study evaluated the primary role of
P. gingivalis in the course of PD and subsequent RA in rats. The authors exposed the rats to oral
inoculation with P. gingivalis and or P. intermedia for one month and then followed for eight months.
PD was developed only in rats that received P. gingivalis. Interestingly, the RA development was
confirmed in rats exposed only to P. gingivalis characterized by inflammatory infiltrate in the ankle
joints with cortical erosions and cortical bone reduction. The authors concluded that oral priming with
P. gingivalis triggered seropositive RA [143]. In line with this study, Maresz et al. have demonstrated
that mice infected with P. gingivalis W83 strain developed antibodies to citrullinated peptides in a
CIA arthritis model [130]. This means that infection with oral bacteria not only aggravates CIA but
also seems to play a role in sensitizing mice to faster disease development and a more severe disease,
with considerably more cartilage and bone damage in the joints. These outcomes were shown to
be determined on the PPAD activity via increased inflammatory reaction and release of host PADs,
leading to generation of citrullinated neo-epitopes. These findings were corroborated by another
study showing that P. gingivalis aggravated the disease severity in an animal mouse model of RA and
augmented the production of citrullinated antigens in the synovium [145].
Our group recently demonstrated a significant aggravation of arthritis severity in mice orally
inoculated with P. gingivalis and P. nigrescens by increasing bone erosions in the affected joints [146].
These results indicate that the Th17 induction strongly depended on the TLR2 expression on
antigen-presenting cells and was highly promoted by the IL-1 production, and stimulation of local
Th17 cell differentiation. Moreover, this data provides evidence of the involvement of PD in the
pathogenesis of the T cell-driven arthritis through induction of a Th17-type response [146]. We recently
verified that oral infection with P. gingivalis aggravates AIA in mice, with aggravated bone erosion in
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the joints, associated with higher frequency of Th17 cells and increased levels of TNF-α and IL-17 [147].
Increased severity of AIA in this study is dependent of the Th17/IL-17 signaling pathway since the
IL-17RA-deficient mice did not show bone loss or cytokine level alterations. The involvement of P.
gingivalis in the activation of the immune system towards the Th17-pathways was further supported by
increasing synovitis, bone erosions, and osteoclast numbers after PD induction with oral inoculation of
live P. gingivalis [133]. For a complete overview in the role of Th17 cells in the pathogenesis of PD and
RA, the review paper by Bunte and Beikler [148] is suggested.
Sato et al. [144] examined whether the modification of gut microbiota induced by P. gingivalis and
P. intermedia, a Gram-negative microorganism also associated with PD that does not express PAD, is
related with CIA. P. gingivalis, but not P. intermedia significantly aggravated CIA, with increased IL-17
levels in the serum, increased proportion of Th17 cells in lymphocytes, and a noteworthy change in the
gut microbiome. Conversely, P. gingivalis did not increase the ACPA levels. These findings point to
an exclusive role of P. gingivalis in the link between RA and PD by affecting the gut microbiota and
inducing a shift to the Th17-type response.
A study using an oral inoculation model of the polymicrobial mixture of P. gingivalis, T. denticola,
and T. forsythia to induce PD has shown that the presence of these bacterial strains exacerbate the
development of CIA in mice [149]. Induction of PD in this study favored the CIA development,
as shown by earlier commencement, and a more aggressive arthritic development associated with
enhanced influx of inflammatory cells and pannus formation. Of importance, the identification of
P. gingivalis in the joint tissues of mice with CIA challenged with periodontal pathogens suggests that
a metastatic infection by PD-associated bacteria might contribute to the progression and severity of
arthritis [149].
Bartold et al. [150] recognized that a combined approach using heat killed P. gingivalis to induce
chronic inflammation followed by an arthritogenic hit to induce RA led to exacerbation of the immune
response and increased severity of arthritis in rats. These findings were different from those described
by Queiroz-Junior et al. [151] that showed no influence of A. actinomycetemcomitans induced-PD on the
progression and severity of chronic AIA in mice. On the other hand, chronic AIA clearly exacerbated
A. actinomycetemcomitans induced-PD. The lack of influence of PD on arthritis progression in this
study [141] compared to the work made by Bartold et al. [150] might be attributed to differences in the
bacterial species (P. gingivalis versus A. actinomycetemcomitans), the specific strain of bacteria used, route
of bacterial infection (oral inoculation versus implantation of sponge impregnated with bacteria in the
back), experimental animal species (mouse versus rat) and arthritis experimental model ( methylated
BSA versus mycobacterium cell wall/adjuvant).
In line with these studies [150,151], Trombone et al. [58] reported that the association between
bacterial induced-PD and pristane-induced RA in rats is dependent on a hyper-inflammatory phenotype.
Interestingly, Queiroz-Junior et al. [152] have shown that AIA in mice provoked spontaneously
inflammatory PD, without manipulation of the oral cavity. There is also evidence that pre-existing PD
induced by oral inoculation with P. gingivalis exacerbated experimental arthritis using the CIA model
in mice [153]. Intriguingly, mice with only PD showed evidence of bone resorption in the radiocarpal
joint, and mice with only collagen-antibody induced arthritis demonstrated alveolar bone loss [153].
Taken together, these studies support the current hypothesis of a biological link between arthritis and
bacterial induced-periodontitis.
5. Therapeutic Association in RA and PD: Epidemiological Studies
NHANES data indicates that the prevalence of PD, estimated by the number of missing teeth, is
four times higher in RA patients [154]. This finding is corroborated by previous epidemiological and
case-control studies, which showed that patients with active RA have significantly increased prevalence
of PD (determined by different criteria, including bleeding, gingivitis, and increased probing pocket
depth) compared to non-RA patients [137,155–160]. In counterpart, the prevalence of RA in PD patients
is higher in comparison with matched periodontally healthy individuals [2,68,73,126,138,161–164].
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Some studies [138,165–167] have shown that treatment of PD improves RA clinical/disease parameters
(DAS28 score, CRP levels) and conversely that treatment of RA may decrease the extent of periodontal
inflammation (Tables 1 and 2). This information strongly suggests that PD and RA are associated, and
also that the nature of this association involves reciprocal biological influences.
5.1. Effects of Treating RA on PD
RA treatment involves various pharmacological approaches. The use of nonsteroidal anti-inflammatory
drugs (NSAIDs—ibuprofen, aspirin and COX-2 inhibitors), glucocorticoids (GC) [168], and synthetic
and biological disease-modifying antirheumatic drugs (DMARDs) such as, methotrexate, sulfasalazine,
TNF-α inhibitors (infliximab, adalimumab, etanercept, certolizumab and golimumab) [169–173], IL-1β
monoclonal antibody (canakinumab) [174], the IL-1 receptor antagonist (anakinra) [175], the humanized
anti-IL-6 receptor antibody (tocilizumab) [176], and Janus Kinase (JAK) inhibitors (tofacitinib) [177–180]
are currently the most prescribed drugs for the RA treatment. These classes of drugs reduce pain,
inflammation and progression of the joint and therefore ameliorate the signs and symptoms of the
disease, enhancing quality of life [114,181].
The long-term use of GC and NSAID by RA patients is associated with immune suppression,
leading to oral changes such as xerostomia and candidiasis [182]. Although there is evidence from
pre-clinical [183,184], and clinical studies [185,186], that drug-induced transient suppression of the
immune response may attenuate PD, prolonged immunosuppression is also associated with a worse
PD status in pre-clinical [187] and clinical studies [188,189]. This is reflected in RA patients, as some
studies report worse periodontal status [73,155,190–192], whereas other studies demonstrate beneficial
effects of the RA treatment (DMARDs) on the PD status. Table 1 summarizes the main outcomes of
clinical trials evaluating the RA treatment in patients with established PD.
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Table 1. Evidence table summarizing the main outcomes of clinical trials evaluating the RA treatment in patients with established PD.
Study Country PatientNumber Objective Study Design Findings Conclusions
Jung et al. (2018) [193] Korea 64
To evaluate the adjunctive
effect of DMARDs in
response to NSPT in RA
patients.
Prospective clinical trial. All patients
received NSPT and only the RA-PD group
received DMARDs. Periodontitis indices
(probing depth, CAL, GI, and BOP) were
evaluated at the baseline and four weeks
later.
Four weeks after NSPT, the periodontal
indices (probing depth reduction, and
CAL gain) were significantly different in
the RA group treated with DMARDs
compared to the systemically healthy
patients.
The study provides clinical
evidence that DMARDs may
have an adjunctive effect on
response to NSPT in patients
with RA.
Ziebolz et al. (2018) [194] Germany 168
To investigate clinical
periodontal findings in
patients with RA under
immunosuppressive
rheumatic medications.
Cross-sectional study. Patients with RA
treated with different immunosuppressive
medications were involved. Periodontal
parameters (probing depth, BOP and
CAL) was measured.
RA medication was associated with
periodontal inflammation, without
differences in PD severity.
Based upon their mechanisms of
action and efficacy in the
reduction of systemic
inflammation associated with
RA-related medications, they
have varying effects on
periodontal inflammation.
Romero-Sanches et al. (2017) [195] Colombia 177
To evaluate the effects of
conventional drug
treatment and anti-TNF
therapy in patients with RA
on microbiological and
periodontal condition.
Prospective clinical trial. RA patients
under anti-TNF therapy and under
DMARD were involved. Periodontal
evaluation (BOP, CAL, probing depth)
and rheumatologic markers (ACPA, RF,
DAS28, ESR and CRP) were measured.
The anti-TNF therapy with methotrexate
resulted in lower extension of CAL.
Increased ACPAs titers were associated
with the presence of periodontal
pathogens. BOP was associated with
elevated CRP levels, and ESR was
associated with a greater probing depth.
RA treatment affect the clinical
condition and subgingival
microbiota.
Ayravainen et al. (2017) [155] Finland 124
To evaluate the role of
antirheumatic medication
in the periodontal health.
Prospective follow up clinical trial. RA
patients treated with synthetic DMARD;
patients with chronic RA treated with
biological DMARDs. Degree of PD
(probing depth, BOP and CAL) and
clinical RA status (DAS28) were
measured.
Periodontal status in patients with RA
was worse compared to the population
controls. Almost 80% of patients with
synthetic DMARDs and 85% of patients
with biological DMARDs suffered from
PD compared to 40% of the controls.
There was no association
between antirheumatic
treatment and periodontal
parameters.
Kobayashi et al. (2015) [196] Japan 60
To compare the periodontal
condition in patients with
RA and PD before and after
treatment with the
anti-human IL-6 receptor
(IL-6R) monoclonal
antibody
(Tocilizumab—TCZ) and
anti-TNF therapy.
Longitudinal case control study. Patients
with RA-PD treated with TCZ and
patients with RA-PD who received the
anti-TNF were involved. Clinical
periodontal (GI, CAL, BOP and probing
depth) and rheumatologic assessments
(DAS28 and CRP) were assessed at the
baseline and three and six months later.
Decreased levels of GI, BOP, and probing
depth in patients with RA-PD after
medication with anti-IL6 and anti-TNF
were observed. Both therapies decreased
DAS28, CRP, the number of tender and
swollen joints, and serum levels of ACPA,
RF, CRP, and MMP-3.
Anti-IL6 therapy significantly
decreased the levels of
periodontal inflammation in
patients with RA-PD.
Coat et al. (2015) [197] France 21
To evaluate the efficacy of
rituximab in the
periodontal parameters of
patients with RA.
A cross-sectional and longitudinal study.
Patients were divided in two groups:
Group 1 received two doses of rituximab
and group 2 received more than two
courses of rituximab. The periodontal
status (BOP, GI, CAL and probing depth)
were measured.
Significant decrease in the probing depth
and CAL were observed after six months
of treatment with rituximab in group 1.
Patients from group 2 presented better
periodontal status than patients from
group 1 before treatment with rituximab.
Anti-IL6 therapy could be
beneficial to improve PD.
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Table 1. Cont.
Study Country PatientNumber Objective Study Design Findings Conclusions
Kobayashi et al. (2014) [198] Japan 20
To assess the effect of the
anti-TNF inhibitor
(adalimumab), on the
periodontal condition of
patients with RA and to
compare the serum protein
profiles before and after
therapy.
Prospective clinical trial. Patients with RA
under the adalimumab treatment were
included. Periodontal indices (GI, BOP,
CAL and probing depth) and
rheumatologic scores (DAS28-CRP) were
measured.
A significant decrease in GI, BOP, probing
depth, DAS28-CRP, and serum levels of
TNF-α and IL-6 after adalimumab
therapy were evidenced.
These findings might suggest a
promising effect of adalimumab
therapy on the periodontal
condition of patients with RA.
Ustun et al. (2013) [199] Turkey 16
To evaluate the effects of
host modulation with the
anti-TNF therapy in
periodontal tissues of
patients with RA.
Longitudinal clinical trial. RA individuals
were included, and periodontal indices
(BOP, CAL, GI, and probing depth), GCF
samples of IL-1β, IL-8 and MCP-1, and
arthritis parameters (DAS28, CRP, and
ESR) were measured at the baseline and
30 days after.
A decrease in the GCF volume, as well as
IL-1β, IL-8, and MCP-1 levels in RA
patients on the anti-TNF therapy was
observed compared to the baseline.
Probing depth and CAL of all patients
remained unchanged. After 30 days of the
anti-TNF therapy, CRP, ESR and DAS28
values were significantly lower compared
to the baseline.
Host modulation might alter
biochemical parameters of the
periodontium in PD patients
even without NSPT.
Mayer et al. (2013) [200] Israel 58
To evaluate the effect of
autoimmune diseases (AD)
treated with anti-TNF on
the clinical and
immunologic parameters of
the periodontium.
Observational clinical trial. Patients with
AD were enrolled (12 RA; 12 psoriatic
arthritis; 12 systemic sclerosis patients).
Ten RA patients were at the anti-TNF
therapy (RA+) and 12 were systemically
health individuals (H). the periodontal
indices (GI, BOP, CAL and probing depth)
and TNF-α levels were measured.
No differences were found among the AD
groups in clinical and immunologic
parameters. GI was increased in the AD
patients compared to the H and RA+
groups. Significantly more BOP and
decreased probing depth in the SD groups
were observed compared to H and RA+.
Increased levels of TNF-α in the AD
groups were seen compared to H and
RA+.
Patients with AD diseases
presented with worse PD and
higher TNF-α levels than the H
controls. Anti-TNF-α treatment
appears to hinder this scenario.
Savioli et al. (2012) [201] Brazil 18
To evaluate the influence
and the evolution of PD in
RA patients treated with
anti-TNF-α.
Longitudinal and prospective clinical. RA
patients on the anti-TNF treatment were
included. Periodontal assessment (GI,
BOP, CAL and probing depth) and
rheumatologic evaluation (DAS28, ESR,
and CRP) were measured at the baseline
and six months later.
Eight out of 18 patients were diagnosed
with PD. Periodontal indices were stable
in the entire group throughout the
experimental period. Significant
improvement in all rheumatologic
parameters were evidenced after six
months of treatment with anti-TNF. This
improvement was restricted to the
individuals without PD.
PD patients did not improve
rheumatologic parameters.
Underlying PD may affect TNF
blockers efficacy in patients with
RA.
Mayer et al. (2009) [202] Israel 30
To investigate the influence
of the anti-TNF-α therapy
on the clinical and
immunologic parameters of
the periodontium.
Longitudinal clinical study including 10
subjects with RA receiving anti-TNF-α; 10
RA patients without biological DMARD
and 10 health control. Periodontal
parameters (GI, BOP, CAL and probing
depth) were measured as well as levels of
TNF-α in GCF and DAS28.
The anti-TNF- α therapy decreased the
GCF levels of TNF-α and lead to milder
PD (decreased probing depth and CAL)
compared to the RA patients who did not
receive this medication. Rheumatologic
markers (DAS28, CCP and RF) were
similar between groups receiving or not
receiving the medication.
Anti-TNF-α agents may halt
periodontal inflammation and
bone resorption.
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Table 1. Cont.
Study Country PatientNumber Objective Study Design Findings Conclusions
Pers et al. (2008) [203] France 40
To investigate the beneficial
effects of anti-TNF-α in RA
patients with coexisting PD.
Cross sectional and longitudinal study.
Patients were divided into: RA patients
that had already started treatment at the
time of periodontal examination and RA
patients that were evaluated before
treatment.
A significant decrease in CAL was
observed in RA patients receiving
anti-TNF-α. On the other hand, increased
gingival inflammation was evidenced in
patients under the infliximab therapy
with the coexisting PD.
Blocking the TNF-α activity
may help in the treatment of PD.
Miranda et al. (2007) [204] Brazil 34
Aiming at comparing the
inflammatory activity in the
GCF of RA patients and to
evaluate the effect of the RA
treatment on PD
Cross sectional observational study.
Seventeen patients were RA positive and
the other half were health control. IL-1β,
-18 and the elastase activity were
measured. RA patients were under
NSAID medication.
Significantly lower amounts of IL-1β and
elastase activity in RA individuals were
observed when compared to the health
control.
The NSAID treatment taken by
RA patients might influence the
PD status by decreasing
inflammatory mediators
commonly seen during the PD
progression.
Disease-modifying antirheumatic drugs (DMARDs), Non-Surgical Periodontal Treatment (NSPT), Rheumatoid Arthritis (RA), Periodontal Disease (PD), Clinical Attachment Loss (CAL),
Gingival Index (GI), Bleeding on Probing (BOP), Tumor Necrosis Factor (TNF), Anti-citrullinated proteins antibodies (ACPA), Rheumatoid Factor (RF), Disease Activity Score including
28-joint count (DAS28), Erythrocyte sedimentation rate (ESR), C-Reactive Protein (CRP), Interleukin (IL), Tocilizumab (TCZ), Metalloproteinase (MMP), systemically diseased (SD), Health
(H), Rheumatoid Arthritis positive patients (RA+).
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Most studies on the influence of the RA treatment on the severity of PD have focused on agents
that target specific molecular factors in the inflammatory cascade, such as biological DMARDs. The
TNF blockers used for the treatment of patients with RA resulted in significant reduction of biochemical
markers of PD including IL-1β and IL-8 in the GCF of patients with established periodontitis [199].
Likewise, the anti-TNF-α treatment decreases periodontal indices and TNF-α levels in the GCF of
patients with both autoimmune disease and periodontitis [200,202]. These studies suggested that the
suppression of TNF-α to treat RA might also be beneficial in ameliorating PD. A systematic review
with the meta-analysis [205] recently verified that the periodontal status of RA patients receiving
antirheumatic medication was better than that of the untreated RA patients. These findings corroborate
previous reports [197,198,206] showing a beneficial effect of adalimumab (a fully humanized monoclonal
antibody), tocilizumab (a humanized monoclonal anti-human IL-6 receptor antibody), and rituximab
(anti-B lymphocyte) therapy on the clinical periodontal conditions, as evidenced by decreased GI, BOP,
and CAL. The treatment of RA patients with DMARDs and anti-TNF decreased the extent of CAL
compared to patients without the treatment [195].
5.2. Effects of Treating PD on RA
The treatment of PD usually does not require pharmacological treatment, and for chronic
periodontitis the mechanical debridement (scaling and root planning) of the microbial biofilm is, for the
majority of cases, the treatment of choice. There is evidence supporting a somewhat limited beneficial
clinical effect with the adjunct use of antibiotics [207]. Regardless, the periodontal treatment aims to
reduce the microbial burden, reduce inflammation and reestablish host-microbial homeostasis.
Several studies have been performed to evaluate the influence of nonsurgical periodontal treatment
(NSPT—oral hygiene instruction and mechanical disruption of microbial from tooth surfaces above
and below the gingival margin) on the course of arthritis. A summary of the study methods and results
obtained from each study is presented in Table 2. A recent systematic review [208] was conducted to
evaluate whether NSPT in patients with both RA and PD offer benefits in terms of clinical activity and
inflammatory markers of RA. A total of eight studies were included in this review and clinical (DAS28)
and serological (ESR, CRP, IL-6 and TNF-α) markers were evaluated before and after treatment. The
outcome of these studies supported a reduction in DAS28 and ESR scores by the periodontal treatment,
while other parameters did not change after PD treatment.
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Table 2. Evidence table summarizing the main outcomes of clinical trials evaluating the effects of nonsurgical periodontal treatment (NSPT) in patients with active RA.
Study Country Patient Number Objective Study Design Findings Conclusions
Cosgarea et al. (2019) [209] Romania 36
To evaluate the effect of
NSPT in patients with RA
and PD.
Prospective, case-controlled trial. The
RA-PD group and the PD group were
treated with scale and root planning
(SRP). At the baseline and at three and six
months after SRP the periodontal status
and RA disease activity were measured.
RA patients presented a statistically
significant decrease in the serum-CRP at
three months. At all time-points, levels of
inflammatory markers in GCF were
higher in the RA-PD than in PD patients.
Only tendencies to reduction of
DAS28 were observed after
three and six months after NSPT.
Kaushal et al. (2019) [210] India 40
To evaluate the effects of
NSPT on the RA
disease activity.
Prospective clinical trial. PD and RA
parameters were examined at the baseline
and eight weeks following NSPT.
Significant reduction in PI, GI, PPD, CAL
and DAS28 scores were observed in
patients that received NSPT compared to
the untreated patients. The serum levels
of ACPA, RF and CRP were not different
between groups.
NSPT improved the RA disease
activity and periodontal clinical
conditions.
Monsarrat et al. (2019) [211] France 22
To assess the effects of
NSPT on the clinical and
biochemical parameters of
the RA disease activity and
quality of life.
Open-label randomized clinical trial.
Patients were allocated to immediate and
delayed NSPT. The DAS28-ESR and
health assessment questionnaire were
employed. The PD and RA parameters
were examined three months
following NSPT.
NSPT did not lead to a significant
reduction of the DAS28-ESR scores in RA
patients with PD. Improvement in all
periodontal parameters were evidenced
after NSPT.
No improvement of the quality
of life after NSPT was noted. No
beneficial effect of NSPT was
observed on patients with
active RA.
Zhao et al. (2018) [212] China 64 To investigate the effects ofNSPT on RA.
Prospective clinical study. Patients were
divided into four groups: PD patients,
RA, RA-PD, and healthy controls. PD and
RA parameters were examined at the
baseline and one month following NSPT.
The RA-PD group had significantly
higher levels of CRP, ACPA, ESR, and
DAS28 than those in the RA group.
NSPT lead to improvement of
rheumatologic parameters in
RA-PD patients. RA showed
little effect on accelerating the
development of PD.
Yang et al. (2018) [213] Taiwan 31
Aiming at investigating the
effect of NSPT on the serum
levels of RA-related
inflammatory markers in
patients with PD.
Prospective clinical trial. Patients were
treated with NSPT and the serum levels
of ACPA, RF, TNF-α, CRP, IL-1β, and
IL-6 were measured at the end of the
treatment.
NSPT significantly reduced the levels of
ACPA and TNF-α in the serum of PD
patients. A positive correlation was noted
between the number of extracted teeth
and the reduction of ACPA and IL-1β
after NSPT.
RA-clinical parameter might be
improved after NSPT.
Balci Yuce et al. (2017) [214] Turkey 53
To evaluate
proinflammatory cytokine
and vitamin D levels in RA
and PD patients before and
after NSPT.
Controlled, parallel-group clinical trial.
Patients were treated with NSPT and
levels of vitamin D, TNF-α, OPG, and
RANKL in GCF and serum
were measured.
After NSPT, the levels of
25-hydroxy-vitamin D were reduced in
RA-PD patients. RANKL and TNF-α
levels in RA patients decreased
after NSPT.
Significant improvements in
clinical parameters after NSPT
in both RA and PD patients
were observed.
Kurgan et al. (2017) [215] Turkey 45
To evaluate the effect of
NSPT on clinical
parameters and GCF levels
of t-PA and PAI-2 in
patients with PD, with or
without RA.
Prospective clinical trial evaluating T-PA,
PAI-2, CRP, DAS28, ESR and periodontal
parameters were measured at the baseline
and three months after NSPT.
All periodontal clinical parameters were
significantly higher in the RA-PD and PD
groups compared with the control group.
NSPT significantly reduced the GCF t-PA
levels in the RA-PD group.
NSPT significantly improves
clinical periodontal parameters
both in RA-PD and in the
PD patients.
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Table 2. Cont.
Study Country Patient Number Objective Study Design Findings Conclusions
Kurgan et al. (2016) [216] Turkey 66
To evaluate whether NSPT
influences the levels of
MMP-8, IL-6 and PGE2 in
the GCF, and serum levels
of RA biomarkers in
patients with RA-PD.
Observational clinical trial. Patients were
evaluated at the baseline and after three
months of NSPT.
The GCF levels of MMP-8, PGE2 and IL-6
were higher in all groups than the control.
After NSPT, there were significant
decreases in the GCF levels of MMP-8,
PGE2 and IL-6 from patients with RA-PD.
NSPT may provide beneficial
effects on local inflammatory
mediators via decreases in the
GCF of inflammatory
biomarkers.
Bıyıkoglu et al. (2013) [217] Turkey 30
To evaluate clinical and
biochemical outcomes of
NSPT on the serum and
GCF in PD patients with or
without RA.
Single-centered interventional study.
Clinical and biochemical periodontal
(IL-1β, and TNF-α) and RA (DAS28)
parameters were obtained at the baseline,
one, three, and six months after NSPT.
The DAS28 decreased significantly after
NSPT in the RA-PD group. The serum
TNF-α of the PD group were significantly
higher than those of RA-PD. After NSPT,
no changes were noted in the levels of
these cytokines. The GCF of the IL-1β
levels decreased in both groups after
NSPT. At six-months, the GCF of the
IL-1β levels were significantly lower than
the baseline.
NSPT might be beneficial in
decreasing local inflammatory
markers of PD and RA.
Okada et al. (2013) [218] Japan 55
To evaluate whether NSPT
affect the serum antibodies
to P. gingivalis and citrulline
levels in relation to the
disease activity of RA.
Interventional and prospective clinical
trial. Periodontal and rheumatologic
parameters and serum levels of cytokine
and inflammatory markers citrulline and
IgG to P. gingivalis were examined at the
baseline and eight weeks later.
The NSPT group exhibited a significantly
greater decrease in DAS28-CRP, the
serum levels of IgG to P. gingivalis, and
citrulline than the control group. The
serum levels of IgG to P. gingivalis were
positively correlated with those of the
ACPA antibodies.
The findings suggest that NSPT
decreases DAS28-CRP and the
serum levels of IgG to P.
gingivalis and citrulline in the
RA patients and may reflect a
role of P. gingivalis in the protein
citrullination.
Erciyas et al. (2013) [165] Turkey 60
Aiming at evaluating the
effects of NSPT on clinical
periodontal measurements
and systemic inflammatory
mediator levels in RA-PD
patients.
Observational prospective cohort study.
Thirty patients were RA-PD with a
moderate to high DAS28 score and the
others were RA-PD with a low DAS28
score. The ESR, CRP, TNF-α levels in
serum, DAS28 and periodontal
parameters were evaluated at the baseline
and after three months of NSPT.
The ESR, CRP, TNF-α levels in serum,
DAS28 and periodontal parameters
exhibited similar and significant
reduction three months after the NSPT.
These findings might indicate
beneficial effects of NSPT in
reducing RA severity as
measured by a significant
decrease in inflammatory
markers in the serum and
DAS28 score in low or moderate
to highly active RA patients
with PD.
Pinho et al. (2009) [219] Brazil 75
To evaluate the effects of
NSPT on clinical and
laboratory parameters in
patients with RA and PD.
Clinical and interventional trial. Patients
were assigned to five groups according to
the presence or absence of RA and PD
and with or without NSPT. Clinical
periodontal indices, DAS28, CRP, ESR
and alpha-1 acid glycoprotein (AAG)
were measured at the baseline, three and
six months after NSPT.
Significant reduction of periodontal
clinical parameters was observed in three
and six months after NSPT. A significant
decrease in the DAS28 scores of patients
with RA-PD were observed when
compared to the RA patients that
underwent NSPT at the baseline and after
three months, but no differences were
found after six months.
NSPT might be considered an
adjunctive approach to reduce
the levels of DAS28 in the RA
patients. No other parameters
for RA (CRP, ESR and AAG)
were significantly affected by
NSPT.
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Table 2. Cont.
Study Country Patient Number Objective Study Design Findings Conclusions
Ortiz et al. (2009) [166] USA 40
To investigate the effect of
NSPT on the signs and
symptoms of RA in patients
treated with or without
anti-TNF-α.
Clinical and interventional trial. RA-PD
patients under the RA treatment were
enrolled. Half of them received NSPT and
the other half did not. Clinical
periodontal parameters and RA disease
activity levels (DAS28 and ESR) were
measured at the baseline and six weeks
later.
NSPT lead to a significant decrease in the
mean DAS28, ESR, and serum TNF-α
levels. No significant decrease in these
parameters were observed in the
untreated control patients. The
anti-TNF-α therapy decreased the clinical
signs of periodontitis characterized by a
reduction in CAL, BOP, probing depth
and GI.
The control of PD and
inflammation by means of NSPT
might contribute to a reduction
in the signs and symptoms of
active RA.
Al Katma et al. (2007) [167] USA 29 To evaluate the impact ofNSPT on the activity of RA.
Prospective clinical trial. Seventeen
RA-PD patients received NSPT and 12 did
not. Patients were under the DMARD
medication. RA measurements (DAS28
and ESR) and PD indices (CAL, probing
depth, BOP, GI) were measured at the
baseline and eight weeks after.
Significant decrease in the DAS28 and
ESR levels were observed in patients
under the NSPT treatment compared to
the untreated control. NSPT led to a
significant improvement in all
periodontal clinical parameters including
PI, GI, BOP, and probing depth.
NSPT might reduce the severity
of periodontal patients with
active RA.
Scale and root planning (SRP), Non-Surgical Periodontal Treatment (NSPT), Rheumatoid Arthritis (RA), Periodontal Disease (PD), Clinical Attachment Loss (CAL), Gingival Index (GI),
Bleeding on Probing (BOP), Gingival Crevicular Fluid (GCF), Tumor Necrosis Factor (TNF), Anti-citrullinated proteins antibodies (ACPA), Rheumatoid Factor (RF), Disease Activity Score
including 28-joint count (DAS28), Erythrocyte sedimentation rate (ESR), C-Reactive Protein (CRP), Interleukin (IL), Metalloproteinase (MMP), Osteoprotegerin (OPG), Receptor Activator
of the Factor Nuclear Kappa B Ligand (RANKK-L), alpha-1 acid glycoprotein (AAG), Immunoglobulin G (IgG).
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Other observational clinical trials [215,216] and the systematic review with meta-analysis [220]
also evaluated the effect of nonsurgical periodontal therapy on RA (and PD) biomarkers. The results
of these studies demonstrated that treatment significantly reduced the levels of MMP-8, PGE2, IL-6,
and t-PA in the GCF of RA patients; however, the systemic biomarkers of RA (ESR, CRP and RF) were
not improved. This finding could be attributed to the use of immune-modulating medications by the
RA patients (e.g., prednisolone and MTX), which would account for the low baseline DAS28 scores.
However, a reduction in the DAS28 and ESR scores in RA patients after NSPT was reported in some
studies [166,167,218].
The cytokine profiles in the serum of patients with PD and RA were investigated and then
compared to healthy controls [221,222]. The serum levels of TNF-α were elevated in patients with
combined RA/PD and were positively correlated with the RA activity and gingival BOP in patients with
moderate to high disease activity. Furthermore, RA patients with increased levels of TNF-α showed
increased BOP and clinical periodontal attachment loss compared to those with normal levels of
TNF-α [223]. It is thus likely that the elevated levels of TNF-α contribute to periodontal inflammation
in patients with RA.
Altogether, biological DMARD therapies might be suggested as an adjunctive approach for
prevention or treatment of PD in patients with arthritis due to the anti-inflammatory effects of this
class of medication in the periodontal tissue. On the other hand, NSPT has limited effects/benefits to
reduce the RA clinical scores. However, interpretation of this evidence is restricted in the majority of
studies because of important limitations, such as: Small number of studies, sample population, criteria
for definition of PD and RA, the observational design of the studies, history of other medications used
to treat RA that might have masked the impact of RA on the development of PD, short follow-up
period, and associated environmental risk factors. For all those reasons, the findings of the current
literature should be interpreted with caution, and therefore, well-controlled, randomized, prospective,
multicenter large clinical trials are required to further corroborate these evidences.
6. Concluding Remarks
A growing body of pre-clinical animal model and epidemiological studies undoubtedly indicated
that there is a strong relationship between RA and PD. The convincing biological correlation between
both diseases can mainly occur by means of: (1) Genetic susceptibility (shared epitope (SE)-coding
HLA-DRB1 allele), (2) microbial status (P. gingivalis bacteria, microbial dysbiosis at distant sites, i.e., gut
microbiome, and the role of citrullination, and ACPA), and (3) inflammatory response (cytokines and
pattern of immune inflammatory response toward the Th17 profile). Despite all of this, not all studies
have detailed the biological mechanisms outlining how PD aggravates RA and vice-versa. In this sense,
researchers should better define these mechanisms and establish cause-and-effect relationships during
the progression of both conditions. This can be accomplished through well-designed pre-clinical
experiments to determine systemic and tissue-specific alterations during RA and PD. Moreover,
large scale, randomized, well-controlled, clinical trials are warranted to evaluate the impact of
the PD treatment on the clinical course of arthritis. This should be done by means of meticulous
clinical evaluation of the periodontal tissues in individuals with RA-PD, to produce a comprehensive
understanding into the oral conditions of these patients. Increased knowledge of the cross-talk between
both diseases could improve the clinical treatment of inflammatory diseases.
Finally, the recognition of the association between RA and PD, and the possible biological
mechanisms involved during the pathogenesis of these conditions play an important role in the
management of patients in need of periodontal and arthritis treatment. This means that the protocol
care for patients in the treatment for RA could be altered to include periodontal examination in those
patients, and in the case of a positive diagnosis of PD, the protocol treatment could be associated with
the resolution of periodontal inflammation by means of NSPT. On the other hand, periodontal patients
that are diagnosed with RA should have improvement of their periodontal status with the medications
taken to treat arthritis, such as biological DMARDs or nonsteroidal anti-inflammatory drugs because
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of its immune-modulatory effects for both diseases. Taken together, rheumatologists and periodontitis
should be aware of this strong association seeking to improve the treatment modalities to achieve
better clinical outcomes.
7. Research Agenda
An increased understanding of the biological interactions and reciprocal influences between
rheumatoid arthritis and periodontitis can contribute to significant advances of the study of the
pathophysiology of both conditions and may also have therapeutic implications for the therapeutic
management of RA and periodontitis. These conditions have various risk factors in common such as
environmental, smoking, socioeconomic status, genetic (SE-coding HLA-DRB1 allele), dysbiosis of gut
and oral microbiome, and inflammatory response; which suggest common pathogenic mechanisms.
Moreover, there is evidence suggesting a role for periodontitis-associated bacteria (P. gingivalis,
A. actinomycetemcomitans, P. intermedia) in citrullination. Since citrullination is characteristically
increased in RA and may also participate in the pathogenesis of periodontitis, it may represent a
biological mechanism bridging reciprocal influences between RA and periodontitis. Below are the key
points of this review:
• Current evidence points to a pivotal role of microbiome in the pathogenesis of inflammatory
conditions and its imbalance may ultimately result in the disease initiation.
• P. gingivalis and A. actinomycetemcomitans are currently the two most important microorganisms
involved in the pathogenesis of PD and RA and are associated with increased citrullination.
Evidence suggests that increased citrullination may also participate in tissue destruction associated
with periodontitis.
• A bidirectional causal relationship between RA and PD is hypothesized, and citrullination may
represent a key mechanism mediating reciprocal influences in this biological intersection.
• Clinical studies suggest that the RA treatment may ameliorate PD. Conversely, there are
controversial reports on the benefits of the PD treatment in the improvement of RA. Clinical
studies are difficult and limited because of a number of biases, particularly in the approach to
control the influence of tobacco use. Studies in never-smokers will provide important information
on the reciprocal effects of therapeutic management of RA and PD.
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Abbreviations
ABL Alveolar bone level
ACPA Anti-citrullinated proteins antibodies
AIA Antigen-induced arthritis
BOP Bleeding on probing
BSA Bovine serum albumin
CAL Clinical attachment level
CIA Collagen-induced arthritis
CRP C-reactive protein
CT Computer tomography
DAS28 Disease Activity Score including 28-joint count
DMARD Disease-modifying antirheumatic drugs
ESR Erythrocyte sedimentation rate
EULAR European league against rheumatism
GC Glucocorticoids
GCF Gingival crevicular fluid
GI Gingival index
GM-CSF Granulocyte macrophage colony-stimulating factor
IgG Immunoglobulin G
IL-1β Interleukin-1β
IL-17 Interluekin-17
IL-6 Interluekin-6
LtxA Leukotoxin A
MAMP Microbe-associated molecular pattern
MMP Matrix metalloproteinase
MRI Magnetic resonance imaging
NHANES National Health and Nutrition Examination Survey
NHS National Health Service
NSAID Non-steroidal anti-inflammatory drugs
NSPT Non-surgical periodontal treatment
PAD Peptidylarginine deiminase
PAMP Pathogen-associated molecular pattern
PD Periodontal disease
PGE2 Prostaglandin E2
PPD Probing pocket depth
RA Rheumatoid arthritis
RANK-L Receptor activator of NF-κB ligand
RF Rheumatoid factor
ROS Reactive oxygen species
SE Shared-epitope
TGF-β Transforming growth factor-β
TNF-α Tumor necrosis factor-α
VAS Visual analogue scale
WT Wild-type
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